Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design

作者：Geisler Tobias^*; Poli Sven; Meisner Christoph; Schreieck Juergen; Zuern Christine S; Naegele Thomas; Brachmann Johannes; Jung Werner; Gahn Georg; Schmid Elisabeth; Baeezner Hansjoerg; Keller Timea; Petzold Gabor C; Schrickel Jan Wilko; Liman Jan; Wachter Rolf; Schoen Frauke; Schabet Martin; Lindner Alfred; Ludolph Albert C; Kimmig Hubert; Jander Sebastian; Schlegel Uwe; Gawaz Meinrad; Ziemann Ulf

来源：International Journal of Stroke, 2017, 12(9): 985-990.

DOI：10.1177/1747493016681019

• ESUS
• stroke
• atrial fibrillation
• apixaban
• NOAC
• aspirin
• intracardiac monitor

Rationale Optimal secondary prevention of embolic stroke of undetermined source is not established. The current standard in these patients is acetylsalicylic acid, despite high prevalence of yet undetected paroxysmal atrial fibrillation.
Aim The ATTICUS randomized trial is designed to determine whether the factor Xa inhibitor apixaban administered within 7 days after embolic stroke of undetermined source, is superior to acetylsalicylic acid for prevention of new ischemic lesions documented by brain magnetic resonance imaging within 12 months after index stroke.
Design Prospective, randomized, blinded, parallel-group, open-label, German multicenter phase III trial in approximately 500 patients with embolic stroke of undetermined source. A key inclusion criterion is the presence or the planned implantation of an insertable cardiac monitor. Patients are 1:1 randomized to apixaban or acetylsalicylic acid and treated for a 12-month period. It is an event-driven trial aiming for core-lab adjudicated primary outcome events.
Study outcomes The primary outcome is the occurrence of at least one new ischemic lesion identified by axial T2-weighted FLAIR magnetic resonance imaging and/or axial DWI magnetic resonance imaging at 12 months when compared with the baseline magnetic resonance imaging. Key secondary outcomes are the combination of recurrent ischemic strokes, hemorrhagic strokes, systemic embolism; combination of MACE including recurrent stroke, myocardial infarction, and cardiovascular death and combination of major and clinically relevant non-major bleeding defined according to ISTH, and change of cognitive function and quality of life (EQ-5D, Stroke Impact Scale).
Discussion Embolic stroke of undetermined source is caused by embolic disease and associated with a high risk of recurrent ischemic strokes and clinically silent cerebral ischemic lesions. ATTICUS will investigate the impact of atrial fibrillation detected by insertable cardiac monitor and the effects of early anticoagulation with apixaban compared with antiplatelet therapy with acetylsalicylic acid on the incidence of new ischemic lesion after embolic stroke of undetermined source.

• 出版日期2017-12